Academic Journal
Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis
| العنوان: | Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis |
|---|---|
| المؤلفون: | Gisela M. Vaitaitis, David H. Wagner |
| المصدر: | Neurology International, Vol 16, Iss 6, Pp 1540-1551 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Medicine LCC:Internal medicine LCC:Neurosciences. Biological psychiatry. Neuropsychiatry |
| مصطلحات موضوعية: | multiple sclerosis, glatiramer acetate, CD40, drug delivery, slow-release, Medicine, Internal medicine, RC31-1245, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571 |
| الوصف: | Background/Objectives: One of the first-line disease-modifying treatments of multiple sclerosis (MS) is Glatiramer Acetate (GA), which requires daily or three-times-weekly subcutaneous injections. Disease progression, while slowed, still occurs with time. Increasing the impact of the treatment while decreasing the frequency of injections would be ideal. The mechanism of action of GA remains undefined. We developed an alternate approach, KGYY6, whose mechanism of action targets the CD40 receptor with promising results in an Experimental Autoimmune Encephalomyelitis (EAE) model. Methods: GA and a CD40-targeting peptide, KGYY6, were formulated as slow-release particles used to treat EAE in C57BL/6 mice. Results: Compared to liquid formulations, the particle formulations vastly improved drug efficacy in both cases, which would be advantageous in treating MS. GA is a combination of randomly generated peptides, in the size range of 5000–9000 Da, using the amino acids E, A, Y, and K. This approach introduces batch differences that impacts efficacy, a persistent problem with GA. KGYY6 is generated in a controlled process and has a motif, K-YY, which could be generated when manufacturing GA. When testing two different lots of GA or KGYY6, the latter performed equally well across lots, while GA did not. Conclusions: Slow-release formulations of both GA and KGYY6 vastly improve the efficacy of both, and KGYY6 is more consistent in efficacy across different lots. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2035-8377 |
| Relation: | https://www.mdpi.com/2035-8377/16/6/114; https://doaj.org/toc/2035-8377 |
| DOI: | 10.3390/neurolint16060114 |
| URL الوصول: | https://doaj.org/article/181650c6f7ed47ed87f57adf5f54fa56 |
| رقم الانضمام: | edsdoj.181650c6f7ed47ed87f57adf5f54fa56 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20358377 |
|---|---|
| DOI: | 10.3390/neurolint16060114 |